Drug intelligence / Profile preview

CKDB-114

Development stage: Preclinical
Lead developer: CKD Bio
Modality: Small Molecules
Administration: Ophthalmic

Overview

CKDB-114 is an investigational drug candidate being developed by CKD Bio for the treatment of dry eye disease. It is currently in the preclinical research and development (R&D) stage and is categorized within the company's API (Active Pharmaceutical Ingredient) sector. While specific mechanistic details have not been disclosed, the candidate is being developed to address ocular surface disorders. CKD Bio specializes in the development and manufacture of APIs through fermentation and chemical synthesis, suggesting the candidate is likely a small molecule or fermentation-derived product.

Beyond the preview

Go deeper on CKDB-114.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CKDB-114.

Explore the full profile